Success Stories: Postdoctoral Scholar in the Field of Pharmaceutical Science in New York Receives EB-2 NIW Approval After Only 43 Days
Client’s Testimonial:
Thank you very much...Really appreciate your help.
On March 5, 2014, A Postdoctoral Scholar in the Field of Pharmaceutical Science Received EB-2 NIW (National Interest Waiver) Approval Only 43 Days After Filing His Case (Approval Notice)
General Field: Pharmaceutical Science
Position at the Time of Case Filing: Postdoctoral Research Scholar
Country of Origin: India
Service Center: Texas Service Center (TSC)
State of Residence at the Time of Filing: New York
Approval Notice Date: March 5, 2014
Processing Time: 43 Days
Case Summary:
North America Immigration Law Group – WeGreened.com represented a postdoctoral scholar in the field of Pharmaceutical Science who designed various inhibitors that can contribute towards the treatment of immune disorders and cancer. This client had also contributed towards the development of a spirohydantoin-based method of treating epilepsy, as well as contributing towards the development of a pharmaceutical inhibitor for the treatment of inflammatory diseases. More recently, he had researched and designed pharmaceutical inhibitors of glucose regulated protein 94, which is related to disorders such as sepsis and autoimmune disease. The aforementioned projects had resulted in 13 peer-reviewed articles, in addition to 13 presentations at national and international conferences. These publications had been cited 65 times at the time of case filing, clearly demonstrating that researchers in the field of Pharmaceutical Sciences rely on the client’s work. This client had retained us to file both his EB-2 NIW and his EB-1A petitions, both of which received approval on March 5, 2014. One recommender explained: “These works integrate his specialties in the areas of pharmaceutical research and medicinal chemistry, and relied on his mastery of advanced techniques such as synthesis, purification, recrystallization, sublimation, chromatography, and characterization of organic compounds through various spectra (UV, IR, MS, NMR). He has also showed great proficiency in cell culture and in-vitro binding studies. These skills have helped him specifically to make advances in the use of spirohydantoins as antiepileptic agents, the development of endothelin-A receptor antagonists as anti -inflammatory agents, and most recently, the development of Hsp90, Grp94, and Hsp70 inhibitors as anticancer agents.” This EB-2 NIW petition received approval after only 43 days.